Multidrug Therapies Containing Monoclonal Antibodies for Multiple Myeloma 2024
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 23 September 2024 | Viewed by 4199
Special Issue Editor
Interests: multiple myeloma; monoclonal gammapathy; immunotherapy; transplant
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Treatment of multiple myeloma (MM) continues to evolve, and immunotherapy has now entered its therapeutic armamentarium. In particular, monoclonal antibodies (MoAbs), such as elotuzumab, daratumumab, and isatuximab in combinations with proteasome inhibitors (PI) and immunomodulatory agents (IMiDs), successfully used for relapsed–relapsed MM, have been used in frontline therapy in both transplant-eligible and -non-eligible patients. Elotuzumab in combination with lenalidomide and dexamethasone (Rd), and subsequently, daratumumab with Rd and with bortezomib and dexamethasone (Vd) were the first to be approved for the treatment of relapsed–refractory MM (rrMM). Recently, another anti-CD38 MoAb named isatuximab was approved by the FDA in combination with pomalidomide–dexamethasone for rrMM. Daratumumab, in combination with bortezomib, melphalan, and prednisone (VMP) as well as with lenalidomide and dexamethasone (Rd), has just been approved for the treatment of newly diagnosed MM patients not eligible for transplantation, since these regimens have been shown to definitely induce better results compared with standard therapies. In transplant-eligible patients, many trials comparing standard treatments with regimens containing elotuzumab, daratumumab, and isatuximab are either ongoing or have concluded with very encouraging results. The new frontier of immunotherapy of MM includes bispecific and conjugated MoAbs, a very promising active area of experimental trials for rrMM patients in which preliminary results are rather favorable. It can be argued that passive and active immunotherapy will make MM a chronic disease or will cure an increasing fraction of MM patients.
Dr. Massimo Offidani
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- monoclonal antibodies
- immunotherapy
